

Ke-Nan Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1086626/publications.pdf>

Version: 2024-02-01

29
papers

1,416
citations

430442

18
h-index

525886

27
g-index

31
all docs

31
docs citations

31
times ranked

1342
citing authors

#	ARTICLE	IF	CITATIONS
1	Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. <i>Journal of Neurosurgery</i> , 2022, 136, 67-75.	0.9	15
2	Prognostic Pathways Guide Drug Indications in Pan-Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 849552.	1.3	0
3	<i>LRRFIP1</i> , an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 873-883.	1.9	1
4	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12.	3.0	439
5	Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. <i>Oncologist</i> , 2021, 26, e1460-e1469.	1.9	21
6	SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. <i>Frontiers in Immunology</i> , 2021, 12, 659659.	2.2	16
7	New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 682535.	1.1	3
8	METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF- κ B to promote the malignant progression of IDH-wildtype glioma. <i>Cancer Letters</i> , 2021, 511, 36-46.	3.2	86
9	YTHDF2 facilitates UBXL1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF- κ B and promote the malignant progression of glioma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 109.	6.9	92
10	Molecular subtype impacts surgical resection in low-grade gliomas: A Chinese Glioma Genome Atlas database analysis. <i>Cancer Letters</i> , 2021, 522, 14-21.	3.2	10
11	Predictive value of MGMT promoter methylation on the survival of TMZ treated κ -mutant glioblastoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 271-282.	1.4	31
12	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580464.	1.8	8
13	Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. <i>Cancer Science</i> , 2020, 111, 2325-2335.	1.7	27
14	RGS16 promotes glioma progression and serves as a prognostic factor. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 791-803.	1.9	24
15	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 314-322.	1.9	42
16	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. <i>Frontiers in Genetics</i> , 2019, 10, 910.	1.1	22
17	Hypoxia induced LBH overexpression accelerates malignant progression in glioma. <i>EBioMedicine</i> , 2019, 49, 4-5.	2.7	1
18	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. <i>Cancer Cell International</i> , 2019, 19, 155.	1.8	27

#	ARTICLE	IF	CITATIONS
19	Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 965-975.	1.9	21
20	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. <i>Carcinogenesis</i> , 2019, 40, 1229-1239.	1.3	60
21	m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. <i>Aging</i> , 2019, 11, 1204-1225.	1.4	209
22	<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10263-10273.	1.0	25
23	ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme. <i>Disease Markers</i> , 2019, 2019, 1-12.	0.6	66
24	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. <i>Modern Pathology</i> , 2019, 32, 4-15.	2.9	41
25	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. <i>JCI Insight</i> , 2019, 5, .	2.3	20
26	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 439-447.	1.2	36
27	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies (Review). <i>Biomedical Reports</i> , 2018, 10, 3-9.	0.9	7
28	ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R. <i>Cancer Cell International</i> , 2018, 18, 196.	1.8	19
29	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. <i>Cancer Cell International</i> , 2018, 18, 107.	1.8	33